hrs4r
 I want to donate
Firma
ANNA BAHÍ-SALAVEDRA
Position
Investigador/a Post-doctoral – R2
Postdoctoral Researchers – R2

Projectes

Codi oficial: La Marató 201912-31 Start date:30/09/2020 Data fi: 30/09/2023 Investigador/a principal: XAVIER ALDEGUER MANTE Organisme finançador: FUNDACIO LA MARATO TV3 Ajuda: 199,812.50 €

Publicacions

Oliver L, Ramió-Pujol S, Amoedo J, Malagón M, Serrano M, Bahí A, Lluansí A, Torrealba L, Busquets D, PARDO, L., Serra-Pagès M, Aldeguer X, Garcia-Gil J

A Novel Grape-Derived Prebiotic Selectively Enhances Abundance and Metabolic Activity of Butyrate-Producing Bacteria in Faecal Samples.

FRONTIERS IN MICROBIOLOGY, 2021, 12, 639948-639948 dx.doi.org/10.3389/fmicb.2021.639948

Lluansí A, Llirós M, Oliver L, Bahí A, Elias-Masiques N, Gonzalez M, Benejam P, Cueva E, Termes M, Ramió-Pujol S, Malagón M, Amoedo J, Serrano M, Busquets D, Torreabla L, Sabat M, Buxó M, Cambra M, Serra-Pagès M, Delgado-Aros S, García-Gil LJ, Elias I, Aldeguer X

In vitro Prebiotic Effect of Bread-Making Process in Inflammatory Bowel Disease Microbiome.

FRONTIERS IN MICROBIOLOGY, 2021, 12, 716307-716307 dx.doi.org/10.3389/fmicb.2021.716307
0

RAID Prediction: Pilot Study of Fecal Microbial Signature With Capacity to Predict Response to Anti-TNF Treatment.

INFLAMMATORY BOWEL DISEASES, 2021, 27, 63-66 dx.doi.org/10.1093/ibd/izab273

Malagón M, Ramió-Pujol S, Serrano M, Amoedo J, Oliver L, Bahí A, Miquel-Cusachs JO, Ramirez M, Queralt-Moles X, Gilabert P, Saló J, Guardiola J, Piñol V, Serra-Pagès M, Castells A, Aldeguer X, Garcia-Gil LJ

New fecal bacterial signature for colorectal cancer screening reduces the fecal immunochemical test false-positive rate in a screening population.

Plos One, 2020, 15 dx.doi.org/10.1371/journal.pone.0243158

Malagón M, Ramió-Pujol S, Serrano M, Serra-Pagès M, Amoedo J, Oliver L, Bahí A, Mas-de-Xaxars T, Torrealba L, Gilabert P, Miquel-Cusachs JO, García-Nimo L, Saló J, Guardiola J, Piñol V, Cubiella J, Castells A, Aldeguer X, Garcia-Gil J

Reduction of faecal immunochemical test false-positive results using a signature based on faecal bacterial markers.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2019, 49, 1410-1420 dx.doi.org/10.1111/apt.15251

Busquets D, Mas-de-Xaxars T, López-Siles M, Martínez-Medina M, Bahí A, Sàbat M, Louvriex R, Miquel-Cusachs JO, Garcia-Gil JL, Aldeguer X

Anti-tumour Necrosis Factor Treatment with Adalimumab Induces Changes in the Microbiota of Crohn's Disease.

JOURNAL OF CROHNS & COLITIS, 2015, 9, 899-906 dx.doi.org/10.1093/ecco-jcc/jjv119

Formulari de contacte

About IDIBGI!

menu